Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

M.D. Anderson Cancer Center clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 7:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
3096
Shown on this page
12
Current sort
Recently updated
Sponsor scope
M.D. Anderson Cancer Center
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within M.D. Anderson Cancer Center. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 553–564 of 3,096 matching trials for sponsor M.D. Anderson Cancer Center.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Lifestyle Behavior Influences Among African American Patients With Stage 0-III Prostate Cancer Survivors and Their Partners

NCT04189770
View directory record Official record
Conditions
Cancer Survivor, Partner, Spouse, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Accelerometer, Ecological Momentary Assessment, Questionnaire Administration, Survey Administration
Device · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Not yet recruiting Not applicable Interventional

Efficacy Of An Inpatient Yoga Therapy Program For Cancer Patients

NCT07776587
View directory record Official record
Conditions
Cancer
Interventions
Yoga Therapy (YT)
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Active, not recruiting Not applicable Interventional

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

NCT02658279
View directory record Official record
Conditions
Glioma, Recurrent Malignant Glioma
Interventions
Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases

NCT01644591
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

NCT07133425
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, ICI-refractory
Interventions
SAR445877
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Recruiting Phase 2 Interventional

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT06940518
View directory record Official record
Conditions
Ivonescimab, Clear Cell Renal Carcinoma
Interventions
Ivonescimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Active, not recruiting Phase 1 Interventional

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

NCT05394259
View directory record Official record
Conditions
Pancreatic Cancer, Breast Cancer, Hepatocellular Carcinoma
Interventions
Piflufolastat F18
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

NCT03274258
View directory record Official record
Conditions
Kidney Medullary Carcinoma, Loss of INI 1 Protein Expression, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Ipilimumab, Nivolumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Not yet recruiting Phase 2 Interventional

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

NCT07137481
View directory record Official record
Conditions
Hematological Malignancies
Interventions
C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Recruiting Phase 1 Interventional

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

NCT05636111
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Paclitaxel, Bevacizumab, Lurbinectedin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Recruiting Phase 2 Interventional

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

NCT07187778
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Pembrolizumab, Belzutifan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Active, not recruiting No phase listed Observational

A Digital Art Activity to Enhance Self-Disclosure and the Detection of Psycho-social Distress in Adult Cancer Patients

NCT06127121
View directory record Official record
Conditions
Cancer
Interventions
Digital Art Activity
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 7:53 PM EDT

About this M.D. Anderson Cancer Center sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where M.D. Anderson Cancer Center is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within M.D. Anderson Cancer Center trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, trials at MD Anderson Cancer Center in Houston, TX, or open the full search for M.D. Anderson Cancer Center.